deferoxamine has been researched along with P carinii Pneumonia in 6 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Because DFO has a short half-life, daily divided or continuous dosage was expected to improve the dose response, as is the case with DFO treatment of malaria." | 1.29 | Response of rat model of Pneumocystis carinii pneumonia to continuous infusion of deferoxamine. ( Chin, K; Clarkson, AB; Grady, RW; Merali, S; Weissberger, L, 1995) |
| "In a rat model of Pneumocystis carinii pneumonia, a 3-week infusion of deferoxamine producing concentrations in plasma of > or = 1." | 1.29 | Trophozoite elimination in a rat model of Pneumocystis carinii pneumonia by clinically achievable plasma deferoxamine concentrations. ( Chin, K; Clarkson, AB; Grady, RW; Merali, S, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Merali, S | 4 |
| Chin, K | 3 |
| Grady, RW | 4 |
| Weissberger, L | 1 |
| Clarkson, AB | 5 |
| Del Angel, L | 1 |
| Armstrong, M | 1 |
| Turkel-Parrella, D | 1 |
| Williams, JH | 1 |
| Chen, LC | 1 |
| Gordon, T | 1 |
| Sarić, M | 1 |
| Kouides, PA | 1 |
| Slapak, CA | 1 |
| Rosenwasser, LJ | 1 |
| Miller, KB | 1 |
6 other studies available for deferoxamine and P carinii Pneumonia
| Article | Year |
|---|---|
Response of rat model of Pneumocystis carinii pneumonia to continuous infusion of deferoxamine.
Topics: Animals; Deferoxamine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration | 1995 |
Clinically achievable plasma deferoxamine concentrations are therapeutic in a rat model of Pneumocystis carinii pneumonia.
Topics: Animals; Antifungal Agents; Chromatography, High Pressure Liquid; Deferoxamine; Lung; Mice; Pneumoni | 1995 |
Trophozoite elimination in a rat model of Pneumocystis carinii pneumonia by clinically achievable plasma deferoxamine concentrations.
Topics: Animals; Antifungal Agents; Deferoxamine; Lung; Pneumocystis; Pneumonia, Pneumocystis; Rats | 1996 |
Action of deferoxamine against Pneumocystis carinii.
Topics: Aerosols; Animals; Chelating Agents; Cytoplasm; Deferoxamine; Half-Life; Humans; Injections, Intrape | 2001 |
Deferoxamine and eflornithine (DL-alpha-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia.
Topics: Animals; Deferoxamine; Disease Models, Animal; Eflornithine; Female; Pneumonia, Pneumocystis; Random | 1990 |
Pneumocystis carinii pneumonia as a complication of desferrioxamine therapy.
Topics: Adult; Deferoxamine; Humans; Male; Pneumonia, Pneumocystis; Thalassemia | 1988 |